Xueqin Hao

Xueqin Hao


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
HZHuijuan Zhao
Huijuan Zhao
ZWZiqing Wei
Ziqing Wei
GSGuomin Shen
Guomin Shen
YCYixiang Chen
Yixiang Chen
XHXueqin Hao
Xueqin Hao
RWRong Wang
Rong Wang
Poly(rC)-binding proteins (PCBPs), a defined subfamily of RNA binding proteins, are characterized by their high affinity and sequence-specific interaction with poly-cytosine (poly-C). The PCBP family comprises five members, including hnRNP K and PCBP1-4. These proteins share a relatively similar structure motif, with triple hnRNP K homology (KH) domains responsible for recognizing and combining C-rich regions of mRNA and single- and double-stranded DNA. Numerous studies have indicated that PCBPs play a prominent role in hematopoietic cell growth, differentiation, and tumorigenesis at multiple levels of regulation. Herein, we summarized the currently available literature regarding the structural and functional divergence of various PCBP family members. Furthermore, we focused on their roles in normal hematopoiesis, particularly in erythropoiesis. More importantly, we also discussed and highlighted their involvement in carcinogenesis, including leukemia and lymphoma, aiming to clarify the pleiotropic roles and molecular mechanisms in the hematopoietic compartment.

14 February 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
HZHuijuan Zhao
Huijuan Zhao
ZWZiqing Wei
Ziqing Wei
GSGuomin Shen
Guomin Shen
YCYixiang Chen
Yixiang Chen
XHXueqin Hao
Xueqin Hao
RWRong Wang
Rong Wang
Corrigendum: Poly(rC)-binding proteins as pleiotropic regulators in hematopoiesis and hematological malignancy

26 April 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
DWDan Wang
Dan Wang
Cheng WangCheng Wang
Cheng Wang
XHXueqin Hao
Xueqin Hao
GCGabriela Carter
Gabriela Carter
RCRafaela Carter
Rafaela Carter
CWChristopher S Wilcox
Christopher S Wilcox
Nuclear factor erythroid factor E2-related factor 2 (Nrf2) transcribes antioxidant genes that reduce the blood pressure (BP), yet its activation with tert-butylhydroquinone (tBHQ) in mice infused with angiotensin II (Ang II) increased mean arterial pressure (MAP) over the first 4 days of the infusion. Since tBHQ enhanced cyclooxygenase (COX) 2 expression in vascular smooth muscle cells (VSMCs), we tested the hypothesis that tBHQ administration during an ongoing Ang II infusion causes an early increase in microvascular COX-dependent reactive oxygen species (ROS) and contractility. Mesenteric microarteriolar contractility was assessed on a myograph, and ROS by RatioMaster™. Three days of oral tBHQ administration during the infusion of Ang II increased the mesenteric microarteriolar mRNA for p47phox, the endothelin type A receptor and thromboxane A2 synthase, and increased the excretion of 8-isoprostane F2α and the microarteriolar ROS and contractions to a thromboxane A2 (TxA2) agonist (U-46,619) and endothelin 1 (ET1). These were all prevented in Nrf2 knockout mice. Moreover, the increases in ROS and contractility were prevented in COX1 knockout mice with blockade of COX2 and by blockade of thromboxane prostanoid receptors (TPRs). In conclusion, the activation of Nrf2 over 3 days of Ang II infusion enhances microarteriolar ROS and contractility, which are dependent on COX1, COX2 and TPRs. Therefore, the blockade of these pathways may diminish the early adverse cardiovascular disease events that have been recorded during the initiation of Nrf2 therapy.

2 November 2024 in Neuroscience Letters
Verified
Journal Article
Closed access
XHXueqin Hao
Xueqin Hao
BDBo Deng
Bo Deng
XHXueqin Hao
Xueqin Hao
XQXiangjun Qiu
Xiangjun Qiu
YLYuanyuan Liu
Yuanyuan Liu

1 December 2024 in Russian Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
DYDong Yan
Dong Yan
XHXixi Hou
Xixi Hou
ZWZiyuan Wu
Ziyuan Wu
XWXinyan Wang
Xinyan Wang
XHXueqin Hao
Xueqin Hao
LMLongfei Mao
Longfei Mao
Dolutegravir, a potent HIV integrase inhibitor, is currently synthesized via routes that have several drawbacks, including low yields, high formation of by-products, and complexities of operations. In this study, we seek to tackle these challenges by developing a new synthesis route for dolutegravir. We designed a new synthesis route based on the existing one, utilizing low-cost starting materials to achieve a dolutegravir production purity of 99.6%. We thus overcome the limitations of the existing synthesis methods and improve the overall efficiency and cost-effectiveness of dolutegravir synthesis.

4 September 2026 in Molecular Brain
Verified
Journal Article
Open access
PDF file
XHXueqin Hao
Xueqin Hao
YFYifan Fu
Yifan Fu
CYChongwei Yang
Chongwei Yang
AGAngyi Guo
Angyi Guo
XLXueting Long
Xueting Long
XXXiaojuan Xie
Xiaojuan Xie
The locus coeruleus (LC), the brain’s principal source of norepinephrine, critically regulates cognitive function. While our previous work established that prenatal lipopolysaccharide (LPS) exposure causes cognitive deficits in rat offspring, the underlying mechanisms and potential therapeutic targets remained unknown. In this study, we found that prenatal LPS exposure enhanced LC neuronal electrical activity and upregulated α2-adrenoceptors, tyrosine hydroxylase in the LC of 15-month-old rat offspring. Concurrently, both the LC and hippocampus exhibited Alzheimer’s disease (AD)-like pathologies, including hyperphosphorylated tau, elevated Aβ42, and increased BACE1 and GSK3β expression in rat offspring. Notably, prenatal dexmedetomidine treatment, a highly selective α2-adrenoceptor agonist, significantly improved cognition and reversed these molecular and electrophysiological alterations. Direct microinjection of dexmedetomidine into the LC similarly suppressed hyperactive LC neurons. In conclusion, α-2 adrenoceptor receptors in LC plays an important role in cognitive deficits induced by prenatal LPS exposure, and Dexmedetomidine might be a promising agent in treating prenatal LPS-induced cognitive deficits in offspring rats.